Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan versus busulfan reduced-intensity conditioning before allogeneic HSCT in AML or MDS
2008-002356-18Phase 3Completed
- Sponsor
- medac GmbH
- Start
- Jun 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of treosulfan and busulfan in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by medac GmbH. Primary endpoint: Event-free survival. Started Jun 2008; status: completed.
02
Drugs
treosulfanbusulfan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2008-002356-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002356-18.